Figure 4.

In vivo pharmacologic activity of BMTP-11 in subcutaneous and lung colonization mouse models of human lung cancer. IL-11R expression was evaluated in the mouse models by immunohistochemistry. A: Representative subcutaneous tumor (left) and corresponding control staining with secondary antibody only (right). B: Lung tumor (left) with evidence of membrane IL-11R staining (left, arrows). C: Effect of BMTP-11 treatment on the growth of subcutaneous primary tumors. Mice received an intravenous administration of 10 mg/kg BMTP-11 or nontargeted _D[KLAKLAK]₂ peptide (control) on days 3 and 10 (arrows). D: Lung weights of mice injected into the tail vein with lung cancer cells and treated with BMTP-11 or control peptide. E: Number of tumors in bilateral lungs dissected from mice treated with either BMTP-11 or control peptide. Data are expressed as mean tumor volumes ± SEM (C). n = 10 treated mice (C–E); n = 10 control mice (C); n = 9 treated mice (D and E); *P < 0.05, **P < 0.01. Scale bars: 100 μm (A and B).